Anteris Technologies Global Corp. has released its financial results for the quarter ended March 31, 2025. The company reported receiving net proceeds of $80 million from its initial public offering, which commenced on December 12, 2024. These funds have been allocated as follows: $20.8 million was directed towards the ongoing development of DurAVR® THV and the preparation and enrollment of the Pivotal Trial for treating severe aortic stenosis, while $10.5 million was used for net working capital and other general corporate purposes, including the repayment of $6.4 million of debt. During the first quarter of 2025, Anteris Technologies incurred payments totaling $1.77 million to related parties and their associates, covering director fees and executive remuneration, which included annual incentive bonuses. These payments were accounted for within cash flows from operating activities. The company emphasizes that there were no payments to related parties or their associates within cash flows from investing activities. The financial statements were prepared in accordance with US GAAP and are presented in U.S. dollars.